Screener
Eligibility screening
Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormo…
8 US sites in CA, IL, MT, OR +3
Before we begin
Who are you filling this out for?
Your answer affects how the questions are phrased.